CN121342995A - 抗FAP-Alpha的人源抗体 - Google Patents

抗FAP-Alpha的人源抗体

Info

Publication number
CN121342995A
CN121342995A CN202511419738.6A CN202511419738A CN121342995A CN 121342995 A CN121342995 A CN 121342995A CN 202511419738 A CN202511419738 A CN 202511419738A CN 121342995 A CN121342995 A CN 121342995A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511419738.6A
Other languages
English (en)
Chinese (zh)
Inventor
杨柳
蒋雯卿
方磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biotechnology Co ltd
Original Assignee
Lepu Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Biotechnology Co ltd filed Critical Lepu Biotechnology Co ltd
Publication of CN121342995A publication Critical patent/CN121342995A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A61K40/4249—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202511419738.6A 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体 Pending CN121342995A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021143087 2021-12-30
CNPCT/CN2021/143087 2021-12-30
CN202280092987.7A CN118974258A (zh) 2021-12-30 2022-12-29 抗fap-alpha的人源抗体
PCT/CN2022/143358 WO2023125796A1 (en) 2021-12-30 2022-12-29 Human antibodies against fap-alpha

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280092987.7A Division CN118974258A (zh) 2021-12-30 2022-12-29 抗fap-alpha的人源抗体

Publications (1)

Publication Number Publication Date
CN121342995A true CN121342995A (zh) 2026-01-16

Family

ID=86998178

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511419738.6A Pending CN121342995A (zh) 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体
CN202280092987.7A Pending CN118974258A (zh) 2021-12-30 2022-12-29 抗fap-alpha的人源抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280092987.7A Pending CN118974258A (zh) 2021-12-30 2022-12-29 抗fap-alpha的人源抗体

Country Status (5)

Country Link
US (1) US20250297032A1 (cg-RX-API-DMAC7.html)
EP (1) EP4457346A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503533A (cg-RX-API-DMAC7.html)
CN (2) CN121342995A (cg-RX-API-DMAC7.html)
WO (1) WO2023125796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CA2401252A1 (en) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
DE10013286A1 (de) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Humane FAP-alpha-spezifische Antikörper
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
PE20171512A1 (es) * 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
CN109796532B (zh) * 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Also Published As

Publication number Publication date
WO2023125796A1 (en) 2023-07-06
CN118974258A (zh) 2024-11-15
JP2025503533A (ja) 2025-02-04
EP4457346A1 (en) 2024-11-06
US20250297032A1 (en) 2025-09-25
EP4457346A4 (en) 2026-07-01

Similar Documents

Publication Publication Date Title
Strohl Current progress in innovative engineered antibodies
WO2023116880A1 (en) Anti-ccr8 antibodies and uses thereof
CN120623346A (zh) Pd-1单结构域抗体及其治疗组合物
JP2024075587A (ja) O-アセチル化GD2ガングリオシド(OAcGD2)に対するヒト化抗体
CN119451988B (zh) 抗b7-h3抗体及其用途
CN118317975A (zh) 靶向baff-r的抗体及其用途
KR20240070496A (ko) 활성화된 간 성상세포(hscs)의 고갈 및 이의 용도
KR20250141223A (ko) Liv-1을 표적화하는 항체 및 이의 용도
CN121620527A (zh) 针对gprc5d的单域抗体
CN118946590A (zh) 抗5t4抗体及其用途
CN119735678B (zh) 肿瘤抗原依赖性cd40激动剂单域抗体
CN118974258A (zh) 抗fap-alpha的人源抗体
CN119654342B (zh) 抗MerTK抗体及其用途
JP2026501783A (ja) Smagp融合分子およびその使用方法
HK40117638A (en) Human antibodies against fap-alpha
HK40117975A (en) Anti-b7-h3 antibodies and uses thereof
HK40117975B (en) Anti-b7-h3 antibodies and uses thereof
WO2025119346A1 (en) Anp-dependent antibodies
WO2025061132A1 (en) Anti-dll3 antibodies and uses thereof
US20260139057A1 (en) Humanized antibodies to human integrin avb8
TW202535953A (zh) 靶向密連蛋白6之抗體及抗體-藥物結合物
HK40112932A (en) Anti-5t4 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2026097087A1 (en) Anti-cd28 antibodies
EP4475880A2 (en) Anti-il13ra2 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination